Rheumatology is a complicated field of medicine. Not only are there more than 100 rheumatic diseases associated with arthritis, there are many conditions which share the same symptoms. In fact, patients who have features or meet the diagnostic criteria of more than one autoimmune disease may be diagnosed with an overlap syndrome. Mixed connective tissue disease (MCTD) is one such overlap syndrome.
What is MCTD?
Mixed connective tissue disease is a rheumatic disease combining clinical features of lupus, scleroderma, polymyositis or dermatomyositis, and/or rheumatoid arthritis. While symptoms may be systemic, they may not be as severe or widespread as compared to if a person developed any one of these diseases alone. In some cases, MCTD may get worse and evolve into classic systemic sclerosis (scleroderma) or lupus. MCTD is more common in women than men (approximately 10:1 ratio) and onset usually occurs between 15 and 35 years of age.
Common clinical signs of MCTD include Raynaud’s phenomenon (which may occur years before other symptoms emerge), pain and/or inflammation of multiple joints, swollen hands/puffy fingers, and myositis (muscle inflammation). Muscle weakness, fevers, and fatigue are also common.
MCTD may cause skin changes such as lupus-like rashes, reddish patches over the knuckles, violet coloring of the eyelids, loss of hair (alopecia), and dilation of small blood vessels around the fingernails or on the face.
Nearly 80% of people with MCTD develop abnormalities in lung function which may lead to breathing difficulties and/or pulmonary hypertension. Potential heart involvement includes pericarditis, myocarditis, and aortic insufficiency.
Patients may also develop problems swallowing, gastrointestinal difficulties, kidney disease, or enlargement of the spleen or liver. Anemia and leukopenia develop in 30-40% of cases.
Neurological abnormalities may include sensory disturbances in various areas of the body (such as trigeminal neuralgia and peripheral neuropathy), seizures, vascular headaches, cerebral thrombosis, or cognitive dysfunction.
Diagnosis and Treatment
The cause of MCTD is unknown and currently there is no cure. When MCTD is suspected, your rheumatologist may order blood tests to measure for anti-U1-RNP and anti-U1-70 kd antibodies and rheumatoid factor, an electromyogram to measure how well nerves and muscles are communicating, and/or muscle biopsy to test for damage to muscle fibers.
MCTD is a chronic and usually mild disease which can be treated symptomatically with nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial drugs, glucocorticoids, or other immunosuppressant medications if the severity of disease justifies it. Patients with mild disease may experience long periods of time when symptoms disappear (remission) and do not require treatment.
Flare-ups and complications may require stronger therapy including higher doses of steroids or long term immunosuppressant therapy. The 10-year survival rate of MCTD is approximately 80%. Pulmonary hypertension is recognized as the most frequent disease-associated cause of death.
What is the difference between MCTD and Undifferentiated Connective Tissue Disease (UCTD)?
With undifferentiated connective tissue disease (UCTD), patients have symptoms and blood test results that point to a systemic autoimmune disorder, but do not have enough features to meet the diagnostic criteria of a well-defined connective tissue disorder (such as RA, lupus, scleroderma). Because they have features from several known diseases but cannot be accurately classified, they are said to be “undifferentiated.”
UCTD is not an overlap syndrome, as is MCTD, in which patients meet the diagnostic criteria of more than one connective tissue disorder. However, in order to fulfill the current diagnostic criteria for UCTD, patients must have had the disease for at last 3 years with lab test results detecting antinuclear antibodies on 2 different occasions. More common symptoms include Raynaud’s phenomenon, joint pain and swelling, skin changes such as photosensitivity, malar rash, alopecia (hair loss), and oral ulcers, low-grade fever, dry eyes or mouth, and CNS symptoms.
UCTD may evolve into a defined connective tissue disease in 20-40% of patients, while 50-60% remain undifferentiated and 10-20% experience a complete remission of symptoms. UCTD is most likely to evolve to a defined disease during the first 3-5 years. The clinical course of UCTD tends to be mild as compared to other defined diseases, with notable exceptions involving life-threatening complications. It is believed that as many as 25% of patients seen by rheumatologists have UCTD.
Amoura Z, Arnaud L. Mixed connective tissue disease. Orphanet. Updated Oct 2009. Retrieved 18 Jul 2014 from http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=809
Berman JR. Undifferentiated Connective Tissue Disease: In-Depth Overview. Hospital for Special Surgery. Retrieved 18 Jul 2014 from http://www.hss.edu/conditions_undifferentiated-connective-tissue-disease-overview.asp
Greidinger EL, Hoffman RW. Mixed Connective Tissue Disease. In: Medscape Drugs and Diseases. Updated 15 Feb 2013. Retrieved 18 Jul 2014 from http://emedicine.medscape.com/article/335815-overview
Hildebrand B, Battafarano DF. Undifferentiated Connective Tissue Disease. In: Medscape Drugs and Diseases. Updated 11 Feb 2014. Retrieved 18 Jul 2014 from http://emedicine.medscape.com/article/334482-overview
Mixed Connective Tissue Disease. National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH). Updated 4 Jun 2014. Retrieved 18 Jul 2014 from http://rarediseases.info.nih.gov/gard/7051/mixed-connective-tissue-disease/resources/1
Schwartz RA, Sysa-Jedrzejowska A, Wozniacka A. Dermatologic Manifestations of Mixed Connective Tissue Disease. In: Medscape Drugs and Diseases. Updated 14 May 2014. Retrieved 18 Jul 2014 from http://emedicine.medscape.com/article/1066445-overview
Published On: July 21, 2014